Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

Clinical trial NCT04140500 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04140500
Sponsor: Hoffmann-La Roche
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumors Metastatic Melanoma Non-small Cell Lung Cancer Esophageal Squamous Cell Carcinoma

Start date: 2019-11-11
Primary completion: 2027-06-30
Enrollment: 170

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.